Related Experiment Video

Updated: Oct 11, 2026

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats
07:41

A Model of Reverse Vascular Remodeling in Pulmonary Hypertension Due to Left Heart Disease by Aortic Debanding in Rats

Published on: March 1, 2022

Mechanisms involved in the hemodynamic alterations in congestive heart failure as a basis for a rational

J Marín1, E Marín, M A Gutiérrez-Iñiguez

  • 1Servicio de Farmacología Clínica, Hospital Universitario Clínica Puerta de Hierro, c/ San Martín de Porres, 4, 28035-Madrid, Spain.

Pharmacology & Therapeutics
|October 18, 2000
PubMed

Insights

Congestive heart failure (CHF) treatment aims to improve quality of life and prolong survival by managing neurohumoral activation. Current and novel drug therapies target compensatory mechanisms to improve patient prognosis.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) is a significant cardiological issue.
  • Neurohumoral activation is a key compensatory mechanism in CHF that can worsen prognosis.
  • Effective treatment is crucial for improving quality of life and survival rates.

Purpose of the Study:

  • To outline current and emerging therapeutic strategies for managing congestive heart failure.
  • To address the complexities of neurohumoral activation in CHF.

Main Methods:

  • Review of established and novel pharmacological agents used in CHF treatment.
  • Discussion of symptomatic and disease-modifying therapeutic approaches.

Main Results:

  • Established drugs include ACE inhibitors, diuretics, digoxin, and beta-agonists.
  • Emerging therapies encompass angiotensin II receptor antagonists, novel beta-blockers, and agents targeting specific pathways like vasopressin and endothelin.

Conclusions:

  • CHF management requires addressing both symptoms and neuroendocrine changes.
  • A range of pharmacological options, both current and novel, are available to improve CHF outcomes.

More Related Videos

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models07:49

A Pacing-Controlled Procedure for the Assessment of Heart Rate-Dependent Diastolic Functions in Murine Heart Failure Models

Published on: July 21, 2023

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...